Rejuvenate Biomed's clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia

Rejuvenate Biomed United Kingdom United States of America Belgium

for more information.

About the RJx-01-101 study

RJx-01-101 is a randomized, double-blind, placebo-controlled clinical trial that successfully met primary and secondary endpoints, demonstrating positive clinical outcome data. Involving 42 healthy male subjects aged 65 to 75 with disuse-induced sarcopenia, the trial confirmed the safety, tolerability, and bioavailability of RJx-01 after 6 weeks of treatment. The Phase 1b study explored RJx-01's impact on various pharmacodynamic parameters, paving the way for further investigations in sarcopenia and related conditions. Following the trial, participants underwent a personalized rehabilitation program.

View original content:https://www.prnewswire.co.uk/news-releases/rejuvenate-biomeds-clinical-trial-demonstrates-the-therapeutic-potential-of-rjx-01-in-sarcopenia-302066442.html